Investigating the Feasibility of Repurposing HIV Antivirals in Adults With Long Covid
Icahn School of Medicine at Mount Sinai
Summary
The trial will test if two repurposed HIV antivirals can reduce symptom burden in adult participants with Long Covid compared to placebo. Viral infection and viral reactivation have been documented in Long Covid. Participants will be randomly allocated to receive antivirals, Truvada (tenofovir disoproxil/emtricitabine, TDF/FTC, Group 1) or Selzentry (Group 2), or a placebo (pill) (Group 3), taken daily for 90 days.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Provision of signed and dated informed consent form * Stated willingness to comply with all study procedures and availability for the duration of the study * Any gender, aged 18+ * Diagnosed with: * Long Covid * Documented clinical history of confirmed or suspected acute SARS-CoV-2 infection a minimum of 6 months prior to contact with the study team * Formal diagnosis of Long Covid from a physician and a history of 6 months of Long COVID symptoms * At least a six-month history of one of the following symptoms following SARS-CoV-2 infection: * headache, memory l…
Interventions
- Drugtenofovir disoproxil/emtricitabine
Participants will take Truvada (TDF/FTC, tenofovir disoproxil/emtricitabine) for 90 days.
- DrugSelzentry
Participants will take Selzentry for 90 days.
- DrugPlacebo
Matching placebo.
Location
- The Cohen Center for Recovery from Complex Chronic Illnesses (CoRE)New York, New York